Tecartus denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tecartus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Tecartus as Non-Formulary — and How to Appeal

Tecartus (brexucabtagene autoleucel) is a medical-benefit oncology infusion product — a CAR-T cell therapy administered at an authorized treatment center under a REMS program — not a retail or specialty pharmacy benefit drug. When BCBS routes Tecartus to a pharmacy-formulary review and issues a "non-formulary" denial, it is frequently a benefit-category routing error: the service should be adjudicated under the medical oncology or major medical benefit, not the pharmacy formulary. Even when the denial is issued under the medical benefit using "non-formulary" framing, the appeal is straightforward: Tecartus is FDA-approved, and BCBS's CAR-T medical policy covers FDA-approved indications when the patient meets the clinical criteria.

## Why This Denial Is Appealable

CAR-T cell therapies are billed and administered as infusion services under the medical benefit (HCPCS codes for CAR-T products are medical-benefit codes). A pharmacy-formulary non-formulary denial applied to a medical-benefit infusion product is a category error. If BCBS is issuing a non-formulary denial under the medical benefit, the appeal must demonstrate that Tecartus is: (a) FDA-approved for the patient's confirmed diagnosis; (b) covered under the applicable BCBS CAR-T medical policy when clinical criteria are met; and (c) not excluded by any applicable formulary exclusion that lawfully applies to medical-benefit oncology infusions.

## Federal Appeal Framework

• Internal appeal: File within 180 days. In the appeal letter, explicitly identify the benefit category under which Tecartus should be adjudicated (medical/oncology infusion benefit) and cite BCBS's own CAR-T medical policy.
• Expedited appeal (72 hours): MCL and B-ALL are time-sensitive malignancies; document clinical urgency for expedited review.
• External review (ACA §2719 / ERISA §503): After adverse internal decision, file for external review within the ~4-month window. Independent reviewers apply clinical standards and the correct benefit-category framework, not formulary-tier constructs.

## Documentation to Gather

1. Benefit-category clarification: Identify the HCPCS code(s) under which Tecartus is being billed; confirm these are medical-benefit codes. Include this in the appeal letter to establish that formulary-tier analysis does not apply. 2. Diagnosis confirmation: Pathology report confirming MCL (cyclin D1, t(11;14)) or adult B-ALL (flow cytometry, cytogenetics, molecular markers) — the FDA-approved on-label indication. 3. Prior-therapy history: Dates and regimens for all prior treatment lines, confirming the prior-therapy requirements in the FDA-approved label are met. 4. Performance status and organ-function: Chart documentation of ECOG performance status and relevant laboratory/cardiac values demonstrating clinical eligibility per the prescribing information. 5. REMS/ATC documentation: Confirmation of FACT-accredited REMS-certified authorized treatment center. 6. Treating oncologist's medical-necessity letter: Confirming FDA-approved indication, NCCN guideline alignment, and that no formulary exclusion lawfully overrides coverage for this FDA-approved medical-benefit oncology service.

## Criteria-Mapping Structure

Obtain BCBS's CAR-T (or hematologic malignancy) medical policy and the Tecartus FDA-approved prescribing information. Address both the benefit-category issue and the clinical-criteria elements:

| Issue | Appeal Response | |---|---| | Non-formulary / wrong benefit category | HCPCS code + medical-benefit billing + BCBS CAR-T policy citation | | FDA approval for patient's diagnosis | FDA approval date + on-label indication | | Prior-therapy requirement | Treatment history table | | Organ-function and performance-status criteria | Chart labs + ECOG note | | FACT-accredited REMS ATC | Treatment-center credential letter |

If BCBS cannot identify a specific formulary exclusion that lawfully applies to a medical-benefit FDA-approved CAR-T infusion, the non-formulary denial has no valid coverage basis and should be overturned on internal appeal.